First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies IRVINE, Calif., Aug. 11, 2021 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended June 30, 2021 and… Continue reading Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results
